Crizotinib is a tyrosine kinase inhibitor. It works by blocking an enzyme called anaplastic lymphoma kinase (ALK). Crizotinib only works in cancer cells that have an overactive version of ALK. About 5 in 100 people (5%) with NSCLC have this. It is called ALK-positive disease